Type 2 diabetes (T2D) is an escalating health problem of enormous proportions. Current therapy is insufficient, as evident from the devastating complications in multiple organs.
The proposed project aims to alleviate this mounting problem by addressing two major needs in current T2D management:
1) the need for individualized treatment of patients, and
2) the need for new drugs that can replace the currently available anti-diabetic drugs in T2D patients who cannot take these due to side effects.
We have developed new chemical compounds which we term `sulforaphanoids´. The current programme aims to progress the development of sulforaphanoids towards clinical studies by selecting sulphoraphanoids with best ADME and toxicity properties, evaluate IP rights and conduct in vivo proof of concept studies.
After this programme the project will be ready for in vivo toxicity analyses as part of the preclinical phase. The cross-disciplinary constellation with Lund University, SciLifeLab and PULS AB has the necessary complementary skills to drive this project through the different stages to clinical phaseIIb with a unique interaction between basic and clinical research as well as business and ADME/toxicity aspects.